Denis V. Rylnikov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Denis V. Rylnikov has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Igor Anatolievich Zolotukhin
Pirogov Russian National Research Medical University
9 shared publications - Evgeny I. Seliverstov
Institute of Surgery of the Pirogov Russian National Research Medical University
8 shared publications - E.S. An
Pirogov Russian National Research Medical University
5 shared publications - Alvina S. Khachatryan
Pirogov Russian National Research Medical University
4 shared publications - I. S. Lebedev
Pirogov Russian National Research Medical University
3 shared publications - Alexandr Kuperin
Pirogov Russian National Research Medical University
2 shared publications
Latest Publications
- 22 September 2026
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 20 (3)
Drug Selection for Long-Term Anticoagulant Therapy in Patients with Venous Thromboembolism
Following completion of the primary phase of anticoagulant therapy (ACT) in patients with venous thromboembolic complications (VTEs), discontinuation of anticoagulant agents significantly increases the risk of recurrent venous thrombosis and pulmonary embolism. This consideration provides a compelling rationale for continuing therapy. However, the long-term use of anticoagulants may lead to hemorrhagic complications, which can be life-threatening. Clinicians are thus faced with the critical challenge of balancing the benefits against the risks associated with long-term therapy, while also developing strategies to shift this balance in favor of benefits. One potential method to improve therapeutic outcomes is selecting the appropriate anticoagulant. While different anticoagulants have similar effectiveness, they also exhibit variable safety profiles and associated risks of hemorrhagic events. This literature review evaluates available data on ACT to identify an anticoagulant that effectively mitigates the risk of VTE progression and recurrence without increasing the risk of bleeding complications. Coagulation factor Xa inhibitors are preferred alternatives to vitamin K antagonists due to their lower need for routine laboratory monitoring, enhanced patient adherence, and lower risk of hemorrhagic complications, allowing dose reductions during long-term ACT while maintaining therapeutic efficacy. Comparisons between apixaban and rivaroxaban, particularly regarding VTE treatment, had been largely confined to observational studies until recently. However, data from a randomized controlled trial assessing treatment outcomes with these two agents during the first 3 months post-venous thrombosis have indicated a superior safety profile for apixaban compared with rivaroxaban.
- 22 September 2026
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 20 (3)
Drug Selection for Long-Term Anticoagulant Therapy in Patients with Venous Thromboembolism
Following completion of the primary phase of anticoagulant therapy (ACT) in patients with venous thromboembolic complications (VTEs), discontinuation of anticoagulant agents significantly increases the risk of recurrent venous thrombosis and pulmonary embolism. This consideration provides a compelling rationale for continuing therapy. However, the long-term use of anticoagulants may lead to hemorrhagic complications, which can be life-threatening. Clinicians are thus faced with the critical challenge of balancing the benefits against the risks associated with long-term therapy, while also developing strategies to shift this balance in favor of benefits. One potential method to improve therapeutic outcomes is selecting the appropriate anticoagulant. While different anticoagulants have similar effectiveness, they also exhibit variable safety profiles and associated risks of hemorrhagic events. This literature review evaluates available data on ACT to identify an anticoagulant that effectively mitigates the risk of VTE progression and recurrence without increasing the risk of bleeding complications. Coagulation factor Xa inhibitors are preferred alternatives to vitamin K antagonists due to their lower need for routine laboratory monitoring, enhanced patient adherence, and lower risk of hemorrhagic complications, allowing dose reductions during long-term ACT while maintaining therapeutic efficacy. Comparisons between apixaban and rivaroxaban, particularly regarding VTE treatment, had been largely confined to observational studies until recently. However, data from a randomized controlled trial assessing treatment outcomes with these two agents during the first 3 months post-venous thrombosis have indicated a superior safety profile for apixaban compared with rivaroxaban.
- 30 April 2026
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 20 (2) , 98-104
Efficacy and Safety of Outpatient Management, Early and Standard Discharge Approaches in Low and Intermediate-Low Risk Patients with Pulmonary Embolism
Outpatient management and early discharge for patients with pulmonary embolism (PE) who are at low and intermediate-low risk for early mortality are emerging approaches that are gaining increased attention. Objective. This study aims to evaluate the efficacy and safety of different management strategies for patients with PE: early hospital discharge, outpatient care, and standard inpatient treatment. Material and methods. The study cohort comprised 127 patients recently diagnosed with PE, categorized into those with hospital stays of 3–4 days (early discharge) or 5 days or more (standard inpatient treatment), as well as patients receiving outpatient care. The primary efficacy outcome measured was the incidence of symptomatic recurrent venous thromboembolism (VTE) and/or VTE-related death following the initiation of anticoagulant therapy. The primary safety outcome assessed was the bleeding rate, along with evaluations of VTE-related and all-cause mortality rates. Results. The outpatient group included 50 patients, the early discharge group 37, and the standard inpatient group 40. The mean ages were 65±10, 63.6±12.1, and 61.5±12.4 years, respectively. No fatal VTE recurrences were reported in any group. Bleeding rates were 2% (1 patient) in the outpatient group, 5.4% (2 patients) in the early discharge group, and 0% in the standard inpatient group (p=1). Re-admission rates were similar across the groups: 2 patients (4%) in the outpatient group, 1 patient (2.7%) in the early discharge group, and 1 patient (2.5%) in the standard inpatient group (p=1). The rates of VTE recurrence were comparable among the groups. Chronic heart failure emerged as the only potential predictor for VTE recurrence (odds ratio [OR] 5.02; 95% confidence interval [CI] 1.03–24.51). Outpatient management did not lead to an increased rate of VTE recurrence (OR 0.63; 95% CI 0.12–3.35). Conclusion. Both outpatient management and early discharge for hemodynamically stable patients with PE at low and intermediate-low risk of 30-day mortality are safe and effective alternatives to standard inpatient treatment.
- 30 April 2026
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 20 (2) , 98-104
Efficacy and Safety of Outpatient Management, Early and Standard Discharge Approaches in Low and Intermediate-Low Risk Patients with Pulmonary Embolism
Outpatient management and early discharge for patients with pulmonary embolism (PE) who are at low and intermediate-low risk for early mortality are emerging approaches that are gaining increased attention. Objective. This study aims to evaluate the efficacy and safety of different management strategies for patients with PE: early hospital discharge, outpatient care, and standard inpatient treatment. Material and methods. The study cohort comprised 127 patients recently diagnosed with PE, categorized into those with hospital stays of 3–4 days (early discharge) or 5 days or more (standard inpatient treatment), as well as patients receiving outpatient care. The primary efficacy outcome measured was the incidence of symptomatic recurrent venous thromboembolism (VTE) and/or VTE-related death following the initiation of anticoagulant therapy. The primary safety outcome assessed was the bleeding rate, along with evaluations of VTE-related and all-cause mortality rates. Results. The outpatient group included 50 patients, the early discharge group 37, and the standard inpatient group 40. The mean ages were 65±10, 63.6±12.1, and 61.5±12.4 years, respectively. No fatal VTE recurrences were reported in any group. Bleeding rates were 2% (1 patient) in the outpatient group, 5.4% (2 patients) in the early discharge group, and 0% in the standard inpatient group (p=1). Re-admission rates were similar across the groups: 2 patients (4%) in the outpatient group, 1 patient (2.7%) in the early discharge group, and 1 patient (2.5%) in the standard inpatient group (p=1). The rates of VTE recurrence were comparable among the groups. Chronic heart failure emerged as the only potential predictor for VTE recurrence (odds ratio [OR] 5.02; 95% confidence interval [CI] 1.03–24.51). Outpatient management did not lead to an increased rate of VTE recurrence (OR 0.63; 95% CI 0.12–3.35). Conclusion. Both outpatient management and early discharge for hemodynamically stable patients with PE at low and intermediate-low risk of 30-day mortality are safe and effective alternatives to standard inpatient treatment.
- 26 March 2026
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 20 (1)
Outpatient Treatment of Hemodynamically Stable Patients with Pulmonary Embolism
Objective. To evaluate the efficacy and safety of outpatient treatment of pulmonary embolism (PE) using standard anticoagulant therapy (ACT) with direct oral anticoagulants. Material and methods. A prospective, observational study was conducted in patients with PE. The analysis included fifty patients with a first-time diagnosis of PE who received outpatient treatment. Outpatient management was defined as discharge from the emergency (diagnostic) department after completion of additional evaluation and confirmation of PE. The primary outcomes were the incidence of symptomatic recurrent venous thromboembolism (VTE) and bleeding events following initiation of ACT. Secondary outcomes included VTE-related mortality and all-cause mortality, readmission to emergency departments, and non-adherence to ACT. Results. The mean age of patients was 65±10 years, with a predominance of women (n=29; 58%). The most common presenting symptoms were lower extremity edema (24%) and dyspnea (16%). PE involved the segmental and subsegmental pulmonary arteries in 84% of patients, submassive PE was diagnosed in 10% of subjects, and massive PE — in 4%. Furthermore, 44 (88%) of patients developed PE in addition to oncological disease. Recurrent VTE within 3 months was observed in 1 (2%) patient. No major or clinically relevant bleeding events occurred, and minor bleeding was reported in 1 (2%) patient. Non-adherence to ACT was noted in 2 (4%) patients. During the study, five deaths (10%) occurred, none of which were VTE-related. Conclusion. Outpatient management of hemodynamically stable patients with pulmonary embolism is effective and safe when proper risk stratification and careful evaluation of individual complication risks are ensured.
- 26 March 2026
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 20 (1)
Outpatient Treatment of Hemodynamically Stable Patients with Pulmonary Embolism
Objective. To evaluate the efficacy and safety of outpatient treatment of pulmonary embolism (PE) using standard anticoagulant therapy (ACT) with direct oral anticoagulants. Material and methods. A prospective, observational study was conducted in patients with PE. The analysis included fifty patients with a first-time diagnosis of PE who received outpatient treatment. Outpatient management was defined as discharge from the emergency (diagnostic) department after completion of additional evaluation and confirmation of PE. The primary outcomes were the incidence of symptomatic recurrent venous thromboembolism (VTE) and bleeding events following initiation of ACT. Secondary outcomes included VTE-related mortality and all-cause mortality, readmission to emergency departments, and non-adherence to ACT. Results. The mean age of patients was 65±10 years, with a predominance of women (n=29; 58%). The most common presenting symptoms were lower extremity edema (24%) and dyspnea (16%). PE involved the segmental and subsegmental pulmonary arteries in 84% of patients, submassive PE was diagnosed in 10% of subjects, and massive PE — in 4%. Furthermore, 44 (88%) of patients developed PE in addition to oncological disease. Recurrent VTE within 3 months was observed in 1 (2%) patient. No major or clinically relevant bleeding events occurred, and minor bleeding was reported in 1 (2%) patient. Non-adherence to ACT was noted in 2 (4%) patients. During the study, five deaths (10%) occurred, none of which were VTE-related. Conclusion. Outpatient management of hemodynamically stable patients with pulmonary embolism is effective and safe when proper risk stratification and careful evaluation of individual complication risks are ensured.
- 26 March 2026
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 20 (1)
Effectiveness of 600 mg Diosmin in Patients with Venous Edema and Symptoms in Real Life Practice
Objective. To evaluate the efficacy and safety of therapy with pure diosmin at a daily dose of 600 mg in symptomatic patients with chronic venous disease (CVD), as well as to evaluate patients’ adherence to the prescribed regimen. Material and methods. A multicenter, prospective, observational study was conducted. It included patients with CVD without skin changes and ulceration who presented with venous symptoms. Patients were prescribed with diosmin at a dose of 600 mg once daily to alleviate venous symptoms and reduce edema. The changes in edema/swelling and overall discomfort from CVD symptoms were assessed with a numeric rating scale (NRS). Treatment satisfaction and therapy adherence were also evaluated. Results. Our study included 1929 (72.5%) women and 731 (27.5%) men, with a mean age of 45.6±10.7 years. The overall discomfort score, assessed with NRS, decreased from 5.9±1.81 points at the first visit to 3.1±1.49 at the second visit (day 30) and 1.3±1.30 at the third visit (day 60) (p<0.0001). By the third visit, venous symptoms were completely relieved in 801 of 2463 (32.5%) patients. Edema/swelling were present in 1854 (69.7%) patients at the first visit, 829 at the second visit and 240 at the third visit (p<0.001). At the final visit, 92.6% of patients rated their treatment as «good» or «excellent». Patient adherence to the prescribed regimen was rated as good or excellent. 12 adverse events (AE) were reported, 9 of them were gastrointestinal, and only 1 AE led to discontinuation of the drug. Conclusion. Diosmin at a daily dose of 600 mg reduces the severity and frequency of venous symptoms and swelling. AE associated with diosmin are rare and, in most cases, do not necessitate discontinuation of treatment. Patients demonstrate high levels of treatment satisfaction and adherence to the prescribed regimen.
- 26 March 2026
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 20 (1)
Effectiveness of 600 mg Diosmin in Patients with Venous Edema and Symptoms in Real Life Practice
Objective. To evaluate the efficacy and safety of therapy with pure diosmin at a daily dose of 600 mg in symptomatic patients with chronic venous disease (CVD), as well as to evaluate patients’ adherence to the prescribed regimen. Material and methods. A multicenter, prospective, observational study was conducted. It included patients with CVD without skin changes and ulceration who presented with venous symptoms. Patients were prescribed with diosmin at a dose of 600 mg once daily to alleviate venous symptoms and reduce edema. The changes in edema/swelling and overall discomfort from CVD symptoms were assessed with a numeric rating scale (NRS). Treatment satisfaction and therapy adherence were also evaluated. Results. Our study included 1929 (72.5%) women and 731 (27.5%) men, with a mean age of 45.6±10.7 years. The overall discomfort score, assessed with NRS, decreased from 5.9±1.81 points at the first visit to 3.1±1.49 at the second visit (day 30) and 1.3±1.30 at the third visit (day 60) (p<0.0001). By the third visit, venous symptoms were completely relieved in 801 of 2463 (32.5%) patients. Edema/swelling were present in 1854 (69.7%) patients at the first visit, 829 at the second visit and 240 at the third visit (p<0.001). At the final visit, 92.6% of patients rated their treatment as «good» or «excellent». Patient adherence to the prescribed regimen was rated as good or excellent. 12 adverse events (AE) were reported, 9 of them were gastrointestinal, and only 1 AE led to discontinuation of the drug. Conclusion. Diosmin at a daily dose of 600 mg reduces the severity and frequency of venous symptoms and swelling. AE associated with diosmin are rare and, in most cases, do not necessitate discontinuation of treatment. Patients demonstrate high levels of treatment satisfaction and adherence to the prescribed regimen.
- 27 December 2025
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 19 (4)
Diosmin and Other Venoactive Drugs: Mechanisms of Action, Current and Future Indications for Use
Venoactive Drugs (VADs) are an integral part of the conservative management of chronic venous diseases (CVD). The mechanism of action of these drugs is well-described. It targets key ways of pathogenesis of CVD, such as loss of venous tone, chronic inflammation in the venous wall and its subsequent remodeling, increased capillary permeability, and insufficient compensatory function of the lymphatic system. The clinical efficacy of VADs concerning quality of life, CVD signs and symptoms, has been demonstrated in numerous randomized controlled trials (RCTs), meta-analyses, and systematic reviews. The incidence of adverse events appears to be low, and the use of VADs is considered a safe method of treatment for CVD symptoms. The most extensively studied group of VADs are flavonoids, which include drugs based on diosmin and rutosides. Diosmin, a principal flavonoid used in drugs, exhibits pleiotropic effects. It slows the degradation of norepinephrine in the venous wall, potentiating its effect and enhancing venous tone. Diosmin possesses anti-inflammatory activity by inhibiting leukocyte adhesion and the synthesis of pro-inflammatory mediators. It decreases capillary and venule permeability, which is directly associated with reduced fluid movement into the tissues. RCTs show that diosmin is effective in managing diseases of other organs and systems which also present with edema.
- 27 December 2025
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 19 (4)
Diosmin and Other Venoactive Drugs: Mechanisms of Action, Current and Future Indications for Use
Venoactive Drugs (VADs) are an integral part of the conservative management of chronic venous diseases (CVD). The mechanism of action of these drugs is well-described. It targets key ways of pathogenesis of CVD, such as loss of venous tone, chronic inflammation in the venous wall and its subsequent remodeling, increased capillary permeability, and insufficient compensatory function of the lymphatic system. The clinical efficacy of VADs concerning quality of life, CVD signs and symptoms, has been demonstrated in numerous randomized controlled trials (RCTs), meta-analyses, and systematic reviews. The incidence of adverse events appears to be low, and the use of VADs is considered a safe method of treatment for CVD symptoms. The most extensively studied group of VADs are flavonoids, which include drugs based on diosmin and rutosides. Diosmin, a principal flavonoid used in drugs, exhibits pleiotropic effects. It slows the degradation of norepinephrine in the venous wall, potentiating its effect and enhancing venous tone. Diosmin possesses anti-inflammatory activity by inhibiting leukocyte adhesion and the synthesis of pro-inflammatory mediators. It decreases capillary and venule permeability, which is directly associated with reduced fluid movement into the tissues. RCTs show that diosmin is effective in managing diseases of other organs and systems which also present with edema.
- Open Access
- 17 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8931
Outpatient Management of Pulmonary Embolism Patients with Direct Oral Anticoagulants: A Systematic Review
Background: Pulmonary embolism (PE) patients are generally admitted to the hospital, which leads to significant burden on healthcare systems. Many PE patients are hemodynamically stable and can be ambulated safely. Direct oral anticoagulants (DOACs) do not need routine laboratory monitoring, which makes them a convenient option for outpatient care. Data on the outpatient management of PE patients using DOACs are scarce. Methods: We conducted a systematic search of MECENTRAL databases to identify randomized controlled trials (RCTs), non-randomized studies (non-RCTs), retrospective studies, reviews, systematic reviews, meta-analyses, and clinical guidelines evaluating the use of DOACs for outpatient treatment of PE patients. Results: A total of 833 publications were identified, and eight studies—two RCTs and six non-RCTs (two retrospective and four prospective)—were finally included. These studies reported rates of bleeding events, recurrent venous thromboembolism (VTE), PE-related mortality, and all-cause mortality among outpatients who received DOACs. No PE-related deaths were reported in any of the included studies. Bleeding events were reported in five studies, and recurrent VTE rates were reported in two studies. Study findings showed that the sPESI score has some disadvantages in selecting patients for home treatment. The quality of the studies varied considerably. A meta-analysis could not be performed due to heterogeneity in the study designs, patient populations, and outcome reporting. While the treatment results favored outpatient management of selected PE patients, no robust conclusions could be drawn from the published data. Conclusions: Outpatient treatment of PE with DOACs has some potential as an approach for managing selected patients. Hestia, POMPE-C and RESI scores are preferable for selecting PE patients for home treatment, but utilizing sPESI as the only tool has to be avoided. Apixaban and rivaroxaban are both safe, with a low bleeding risk. Large-scale prospective studies are required to establish the efficacy and safety of outpatient PE management using DOACs.
- 17 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8931
Open AccessOutpatient Management of Pulmonary Embolism Patients with Direct Oral Anticoagulants: A Systematic Review
Background: Pulmonary embolism (PE) patients are generally admitted to the hospital, which leads to significant burden on healthcare systems. Many PE patients are hemodynamically stable and can be ambulated safely. Direct oral anticoagulants (DOACs) do not need routine laboratory monitoring, which makes them a convenient option for outpatient care. Data on the outpatient management of PE patients using DOACs are scarce. Methods: We conducted a systematic search of MECENTRAL databases to identify randomized controlled trials (RCTs), non-randomized studies (non-RCTs), retrospective studies, reviews, systematic reviews, meta-analyses, and clinical guidelines evaluating the use of DOACs for outpatient treatment of PE patients. Results: A total of 833 publications were identified, and eight studies—two RCTs and six non-RCTs (two retrospective and four prospective)—were finally included. These studies reported rates of bleeding events, recurrent venous thromboembolism (VTE), PE-related mortality, and all-cause mortality among outpatients who received DOACs. No PE-related deaths were reported in any of the included studies. Bleeding events were reported in five studies, and recurrent VTE rates were reported in two studies. Study findings showed that the sPESI score has some disadvantages in selecting patients for home treatment. The quality of the studies varied considerably. A meta-analysis could not be performed due to heterogeneity in the study designs, patient populations, and outcome reporting. While the treatment results favored outpatient management of selected PE patients, no robust conclusions could be drawn from the published data. Conclusions: Outpatient treatment of PE with DOACs has some potential as an approach for managing selected patients. Hestia, POMPE-C and RESI scores are preferable for selecting PE patients for home treatment, but utilizing sPESI as the only tool has to be avoided. Apixaban and rivaroxaban are both safe, with a low bleeding risk. Large-scale prospective studies are required to establish the efficacy and safety of outpatient PE management using DOACs.
- 6 June 2025
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 19 (2)
Risk Factors of Hyperpigmentation and Telangiectatic Matting Persistence after Sclerotherapy in C1 Patients
Hyperpigmentation and telangiectatic matting are frequent adverse events after sclerotherapy in C1 patients. Venous specialists need to identify the risk factors of these adverse events. Objective. To identify the risk factors predisposing to persistent hyperpigmentation and telangiectatic matting after sclerotherapy in C1 patients. Material and methods. A database of 72 C1 patients who undergone sclerotherapy were assessed. The analysis included the following variables: age, body mass index (BMI), duration of the disease, number of sclerotherapy procedures, amount of sclerosing agent used, prolonged compression. Long-term compression implied wearing compression hosiery for 3 days after each procedure, as well as for at least 5 days throughout 4 months after the first procedure. In other cases, patients used compression only for 3 days after each sclerotherapy procedure. Class 2 stockings were used for compression. Results. After 4 months, hyperpigmentation and telangiectatic matting persisted in 12 (16.7%) and 7 (9.7%) patients, respectively. Prolonged post-procedural compression was used by 2 (16.7%) patients with persisted hyperpigmentation and 34 (57.7%) patients without hyperpigmentation (p=0.012). One (14%) patient with persisted telangiectatic matting wore compression stockings for a long time while 35 (58%) patients with this complication used short-term compression (p=0.107). Mean BMI was 25.2±5.4 kg/m2 in patients with hyperpigmentation and 22.2±3.2 kg/m2 in those without hyperpigmentation (p=0.089). In patients with and without persisted telangiectatic matting, BMI was 25.2±4.5 and 22.4±3.6 kg/m2, respectively. The only found risk factor that had an impact on persistence of hyperpigmentation and teleangiectatic matting was prolonged compression therapy in the post–procedural period — 0.09 (95% CI: 0.01—0.63; p=0.015) for hyperpigmentation and 0.09 (95% CI: 0.01—1.0; p=0.05) for telangiectatic matting. Conclusions. The risk of persistent hyperpigmentation and telangiectatic matting after sclerotherapy in C1 patients is significantly reduced by prolonged wearing of compression stockings after treatment.
- 6 June 2025
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 19 (2)
Risk Factors of Hyperpigmentation and Telangiectatic Matting Persistence after Sclerotherapy in C1 Patients
Hyperpigmentation and telangiectatic matting are frequent adverse events after sclerotherapy in C1 patients. Venous specialists need to identify the risk factors of these adverse events. Objective. To identify the risk factors predisposing to persistent hyperpigmentation and telangiectatic matting after sclerotherapy in C1 patients. Material and methods. A database of 72 C1 patients who undergone sclerotherapy were assessed. The analysis included the following variables: age, body mass index (BMI), duration of the disease, number of sclerotherapy procedures, amount of sclerosing agent used, prolonged compression. Long-term compression implied wearing compression hosiery for 3 days after each procedure, as well as for at least 5 days throughout 4 months after the first procedure. In other cases, patients used compression only for 3 days after each sclerotherapy procedure. Class 2 stockings were used for compression. Results. After 4 months, hyperpigmentation and telangiectatic matting persisted in 12 (16.7%) and 7 (9.7%) patients, respectively. Prolonged post-procedural compression was used by 2 (16.7%) patients with persisted hyperpigmentation and 34 (57.7%) patients without hyperpigmentation (p=0.012). One (14%) patient with persisted telangiectatic matting wore compression stockings for a long time while 35 (58%) patients with this complication used short-term compression (p=0.107). Mean BMI was 25.2±5.4 kg/m2 in patients with hyperpigmentation and 22.2±3.2 kg/m2 in those without hyperpigmentation (p=0.089). In patients with and without persisted telangiectatic matting, BMI was 25.2±4.5 and 22.4±3.6 kg/m2, respectively. The only found risk factor that had an impact on persistence of hyperpigmentation and teleangiectatic matting was prolonged compression therapy in the post–procedural period — 0.09 (95% CI: 0.01—0.63; p=0.015) for hyperpigmentation and 0.09 (95% CI: 0.01—1.0; p=0.05) for telangiectatic matting. Conclusions. The risk of persistent hyperpigmentation and telangiectatic matting after sclerotherapy in C1 patients is significantly reduced by prolonged wearing of compression stockings after treatment.
- 13 September 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (3)
Anticoagulant Therapy Flaws in Hospitalized Patients with Proximal Deep Vein Thrombosis and Their Impact on the Treatment Outcomes
Objective. To assess the effect of the adequacy of anticoagulant therapy (ACT) on the risk of pulmonary embolism (PE) in patients with proximal deep vein thrombosis. Material and methods. The analysis of a database consisting of 223 patients with proximal venous thrombosis (the thrombus location was not lower than the superficial femoral vein) was carried out. The types of detected ACT flaws and their frequency were analyzed. The role of ACT flaws in episodes of bleeding, thrombosis progression, PE, and deaths was evaluated. Results. Of the 223 patients, there were 97 women (43.5%) and 126 men (56.5%). The mean age was 63.4±16.2 years, the average hospital stay was 6.8±2.7 days. Flaws in the ACT were found in 36.3% (81 people) of cases. Among the identified flaws were: an increase in activated partial thromboplastin time (aPTT) by more than 2.5 times — 12 (5.4%) patients, lack of aPTT control in the first 3 days with unfractionated heparin (UFH) therapy — 40 people (17.9%), lack of achievement of target aPTT values in the first 3 days with UFH therapy — 20 people (13%), therapy with a reduced dose of rivaroxaban 20 mg / day in the acute phase of thrombosis without indications for dose reduction — 2 people (1.3%). 2 episodes of symptomatic PE have been recorded. In the first case, there were no ACT flaws, in the second, clinical manifestations of PE occurred in a patient receiving UFH with aPTT values equal to 26—27 seconds. There were no deaths and bleedings. In 40 patients (17.9%), an increase in the level of thrombosis was recorded against the background of ACT. The results of the logistic regression analysis showed that a statistically significant factor in increasing the level of thrombosis is the start of an act with UFH — the odds ratio is 2.52 (95% CI: 1.11—5.74) (p=0.0271). Conclusion. Most often, ACT flaws occur when UFH is prescribed due to its poorly predictable pharmacokinetics and the need for laboratory monitoring. Even though the performed ACT often has defects, it is still able to prevent the progression of VTE in most cases. Even an adequate ACT is not guaranteed to prevent an embolism.
- 13 September 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (3)
Anticoagulant Therapy Flaws in Hospitalized Patients with Proximal Deep Vein Thrombosis and Their Impact on the Treatment Outcomes
Objective. To assess the effect of the adequacy of anticoagulant therapy (ACT) on the risk of pulmonary embolism (PE) in patients with proximal deep vein thrombosis. Material and methods. The analysis of a database consisting of 223 patients with proximal venous thrombosis (the thrombus location was not lower than the superficial femoral vein) was carried out. The types of detected ACT flaws and their frequency were analyzed. The role of ACT flaws in episodes of bleeding, thrombosis progression, PE, and deaths was evaluated. Results. Of the 223 patients, there were 97 women (43.5%) and 126 men (56.5%). The mean age was 63.4±16.2 years, the average hospital stay was 6.8±2.7 days. Flaws in the ACT were found in 36.3% (81 people) of cases. Among the identified flaws were: an increase in activated partial thromboplastin time (aPTT) by more than 2.5 times — 12 (5.4%) patients, lack of aPTT control in the first 3 days with unfractionated heparin (UFH) therapy — 40 people (17.9%), lack of achievement of target aPTT values in the first 3 days with UFH therapy — 20 people (13%), therapy with a reduced dose of rivaroxaban 20 mg / day in the acute phase of thrombosis without indications for dose reduction — 2 people (1.3%). 2 episodes of symptomatic PE have been recorded. In the first case, there were no ACT flaws, in the second, clinical manifestations of PE occurred in a patient receiving UFH with aPTT values equal to 26—27 seconds. There were no deaths and bleedings. In 40 patients (17.9%), an increase in the level of thrombosis was recorded against the background of ACT. The results of the logistic regression analysis showed that a statistically significant factor in increasing the level of thrombosis is the start of an act with UFH — the odds ratio is 2.52 (95% CI: 1.11—5.74) (p=0.0271). Conclusion. Most often, ACT flaws occur when UFH is prescribed due to its poorly predictable pharmacokinetics and the need for laboratory monitoring. Even though the performed ACT often has defects, it is still able to prevent the progression of VTE in most cases. Even an adequate ACT is not guaranteed to prevent an embolism.
- 17 June 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (2)
Embolic Risk of Deep Vein Thrombosis is not Related to the Nature of Proximal Clot
Despite clinical guidelines not recognizing floating clots as an absolute indication for surgical prevention of pulmonary embolism (PE), many specialists adhere to active surgical approach in such cases. OBJECTIVE To evaluate the incidence of symptomatic PE in patients with proximal embolic (floating) thrombus under standard anticoagulation. MATERIAL AND METHODS We analyzed patients with proximal venous thrombosis above the femoral vein. The main group (embolic thrombosis) included 60 patients with floating clot length of 9.3±2.3 cm, the control group (non-embolic thrombosis) — 164 patients with floating clot length of 2.2±2.2 cm (pp=0.029). Proximal level of thrombosis below the inguinal ligament was found in 49 (81.6%) and 102 (62%) patients, respectively (p=0.006). Mean hospital-stay was 9.2±3.3 and 6.0±1.9 days, respectively (pp=0.952). There were no deaths in both groups. CONCLUSION Incidence of symptomatic PE is similar in patients with embolic and non-embolic deep vein thrombosis receiving adequate anticoagulation in accordance with clinical guidelines.
- 17 June 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (2)
Embolic Risk of Deep Vein Thrombosis is not Related to the Nature of Proximal Clot
Despite clinical guidelines not recognizing floating clots as an absolute indication for surgical prevention of pulmonary embolism (PE), many specialists adhere to active surgical approach in such cases. OBJECTIVE To evaluate the incidence of symptomatic PE in patients with proximal embolic (floating) thrombus under standard anticoagulation. MATERIAL AND METHODS We analyzed patients with proximal venous thrombosis above the femoral vein. The main group (embolic thrombosis) included 60 patients with floating clot length of 9.3±2.3 cm, the control group (non-embolic thrombosis) — 164 patients with floating clot length of 2.2±2.2 cm (pp=0.029). Proximal level of thrombosis below the inguinal ligament was found in 49 (81.6%) and 102 (62%) patients, respectively (p=0.006). Mean hospital-stay was 9.2±3.3 and 6.0±1.9 days, respectively (pp=0.952). There were no deaths in both groups. CONCLUSION Incidence of symptomatic PE is similar in patients with embolic and non-embolic deep vein thrombosis receiving adequate anticoagulation in accordance with clinical guidelines.
- 18 March 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (1)
Embolism-Threatening Thrombosis: Is There Such a Problem?
The review is devoted to modern literature data on floating venous thrombosis. Historical data regarding surgical venous disconnection and recanalization are presented. The authors reviewed modern studies devoted to embolism-threatening thrombosis and appropriate international recommendations. Deep vein thrombosis (DVT) of the lower extremities and pelvis is characterized by clotting in appropriate veins. Pulmonary embolism (PE) is the main and life-threatening complication of DVT. Floating thrombosis is believed to be very dangerous for many years and absolutely requires surgical prevention of PE. Nevertheless, appropriate data are contradictory. Most professional communities recognize impossible anticoagulation as the only indication for cava filter implantation. National guidelines (2023) do not recognize proximal floating thrombus as the only indication for cava filter implantation. Unclear role of floating clots as a risk factor for PE forces specialists to continue cava filter implantation in these cases to this day. Importantly, percutaneous cava filter implantation is really not always possible. This fact requires more invasive partial and complete disconnection with higher incidence of complications, such as ligation of superficial femoral vein, plication of inferior vena cava and open thrombectomy. These features inspired us to analyze venous thrombosis as a risk factor of pulmonary embolism.
- 18 March 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (1)
Embolism-Threatening Thrombosis: Is There Such a Problem?
The review is devoted to modern literature data on floating venous thrombosis. Historical data regarding surgical venous disconnection and recanalization are presented. The authors reviewed modern studies devoted to embolism-threatening thrombosis and appropriate international recommendations. Deep vein thrombosis (DVT) of the lower extremities and pelvis is characterized by clotting in appropriate veins. Pulmonary embolism (PE) is the main and life-threatening complication of DVT. Floating thrombosis is believed to be very dangerous for many years and absolutely requires surgical prevention of PE. Nevertheless, appropriate data are contradictory. Most professional communities recognize impossible anticoagulation as the only indication for cava filter implantation. National guidelines (2023) do not recognize proximal floating thrombus as the only indication for cava filter implantation. Unclear role of floating clots as a risk factor for PE forces specialists to continue cava filter implantation in these cases to this day. Importantly, percutaneous cava filter implantation is really not always possible. This fact requires more invasive partial and complete disconnection with higher incidence of complications, such as ligation of superficial femoral vein, plication of inferior vena cava and open thrombectomy. These features inspired us to analyze venous thrombosis as a risk factor of pulmonary embolism.